Kuo Wei-Chen, Keegan Robert D
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Washington State University, Pullman, WA 99164, USA.
Am J Vet Res. 2004 Jul;65(7):931-7. doi: 10.2460/ajvr.2004.65.931.
To compare sedative, analgesic, and cardiopulmonary effects after IV administration of medetomidine (20 microg/kg), medetomidine-hydromorphone (20 microg of medetomidine/kg and 0.1 mg of hydromorphone/kg), and medetomidine-butorphanol (20 microg of medetomidine/kg and 0.2 mg of butorphanol tartrate/kg) in dogs.
6 dogs healthy mixed-breed dogs.
Instruments were surgically inserted, and heart rate (HR), respiratory rate (RR), systolic arterial pressure (SAP), mean arterial pressure (MAP), diastolic arterial pressure (DAP), mean pulmonary arterial pressure (MPAP), pulmonary capillary wedge pressure (PCWP), central venous pressure (CVP), core body temperature, and cardiac output (CO) were measured 0, 5, 10, 15, 30, 45, and 60 minutes after injection. Cardiac index (CI), stroke volume (SV), stroke index (SI), systemic vascular resistance (SVR), and pulmonary vascular resistance (PVR) were calculated. Arterial samples for blood gas analysis were collected 0, 15, and 45 minutes after injection. Intensity of analgesia, degree of sedation, and degree of muscle relaxation were evaluated at aforementioned time points and 75, 90, 120, 150, 180, and 210 minutes after injection.
Administration of medetomidine, medetomidine-hydromorphone, and medetomidine-butorphanol was associated with increases in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature, and PaCO2 and decreases in HR, CO, CI, SV, SI, RR, pH, and PaO2. Clinically important differences were not detected among treatments. Medetomidine-hydromorphone and medetomidine-butorphanol provided a longer duration of sedation and better quality of analgesia, compared with medetomidine alone.
Medetomidine-hydromorphone or medetomidine-butorphanol is associated with improved analgesia and sedation but has cardiopulmonary effects comparable to those for medetomidine alone.
比较静脉注射美托咪定(20微克/千克)、美托咪定-氢吗啡酮(美托咪定20微克/千克和氢吗啡酮0.1毫克/千克)以及美托咪定-布托啡诺(美托咪定20微克/千克和酒石酸布托啡诺0.2毫克/千克)后对犬的镇静、镇痛及心肺效应。
6只健康杂种犬。
手术植入仪器,于注射后0、5、10、15、30、45和60分钟测量心率(HR)、呼吸频率(RR)、收缩压(SAP)、平均动脉压(MAP)、舒张压(DAP)、平均肺动脉压(MPAP)、肺毛细血管楔压(PCWP)、中心静脉压(CVP)、核心体温及心输出量(CO)。计算心脏指数(CI)、每搏输出量(SV)、每搏指数(SI)、全身血管阻力(SVR)及肺血管阻力(PVR)。于注射后0、15和45分钟采集动脉血样进行血气分析。在上述时间点以及注射后75、90、120、150、180和210分钟评估镇痛强度、镇静程度及肌肉松弛程度。
美托咪定、美托咪定-氢吗啡酮及美托咪定-布托啡诺的给药均与SAP、MAP、DAP、MPAP、PCWP、CVP、SVR、PVR、核心体温及PaCO2升高以及HR、CO、CI、SV、SI、RR、pH及PaO2降低相关。各治疗组间未检测到具有临床意义的差异。与单独使用美托咪定相比,美托咪定-氢吗啡酮和美托咪定-布托啡诺的镇静持续时间更长,镇痛质量更好。
美托咪定-氢吗啡酮或美托咪定-布托啡诺可改善镇痛和镇静效果,但其心肺效应与单独使用美托咪定相当。